Back to CVE records
Critical 9.8HealthcarePublished Mar 26, 2019

CVE-2014-5434Baxter SIGMA Spectrum Infusion System version 6.05 (model 35700BAX) with wireless battery module (WBM) version 16 has a default account with hard-coded credentials used with the FTP protocol.

Updated under an hour ago ()

Does this affect you?

It affects Baxter SIGMA Spectrum Infusion System and 1 other product. Add what you run to find out whether that includes you.

EPSS puts the chance of exploitation in the next 30 days at 1.56%, higher than 75% of scored CVEs.

Baxter SIGMA Spectrum Infusion System version 6.05 (model 35700BAX) with wireless battery module (WBM) version 16 has a default account with hard-coded credentials used with the FTP protocol. Baxter asserts no files can be transferred to or from the WBM using this account. Baxter has released a new version of the SIGMA Spectrum Infusion System, Version 8, which incorporates hardware and software changes.

CVSS
9.8 CRITICAL (v3.0, NVD)CVSS:3.0/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-259
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
1.56% (percentile 75)
Assigned by
icscert
NVD analysis
Modified
Record last updated
Aug 6, 2024
First seen by InfoSec Signals
Oct 12, 2026

Affected products

Affected products
Baxter SIGMA Spectrum Infusion System
baxter:sigma_spectrum_infusion_system (from the name)
6.05 (model 35700BAX) with wireless battery module (WBM) version 16
CNA record
baxter sigma_spectrum_infusion_system_firmware
baxter:sigma_spectrum_infusion_system_firmware
6.05
NVD

References

  • x-refsource-misc, mitigation, third-party-advisory, us-government-resource

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.